Comparing Blood Thinner Levels in People with Irregular Heartbeat
Measures how apixaban and rivaroxaban levels stay steady in adults with atrial fibrillation.
Plain-language title generated from the registry record
Registry title: Apixaban Versus Rivaroxaban in Non Valvular Atrial Fibrillation
Key facts
- Where
- Tunis, TunisiaSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06862726, who can take part
Where in Tunisia
- Charles Nicolle hospitalTunis, TunisiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Les Laboratoires des Médicaments Stériles
- Trial code
- NCT06862726
- Record updated
- 6 March 2025
- Original description
The investigators will first measure the maximum concentration (after 2 hours of intake) and the residual concentration (just before the next intake) after at least 15 consecutive days of treatment.Read full original descriptionShow less
Study of the Inter- and Intra-individual Variability of Anti-Xa Activity of Apixaban Versus Rivaroxaban Versus Control Arm During Non-valvular Atrial Fibrillation: Evaluation of Stability and Clinical Impact
The investigators will first measure the maximum concentration (after 2 hours of intake) and the residual concentration (just before the next intake) after at least 15 consecutive days of treatment.
In order to be able to study the stability of the anti-Xa activity of Apixaban vs Rivaroxaban, as well as their impact on the risk of thromboembolic events or hemorrhagic events, clinical follow-up and a determination of maximum and residual activity are necessary, ideally at 3 to 6 months (compared to studies carried out in the literature).
This evaluation would be made according to a multivariate analysis taking into consideration the other clinical-biological data relating to the patient, namely renal function, liver function, CHA2DS2-VASc score, HAS-BLEED score, treatment compliance, etc.
Inclusion: Male or female ≥ 18 years of age; Patients diagnosed with AF; Written informed consent obtained prior to participation in the study.
Exclusion: Patients receiving combination therapy of P-glycoprotein inhibitors or inducers such as itraconazole, ketoconazole, voriconazole, posaconazole, ritonavir, rifampicin, phenytoin, phenobarbital, and carbamazepine, within 14 days prior to taking apixaban; History of hypersensitivity to study drugs or drugs with a similar chemical structure; Patients with at least one of the following criteria will not be included in the trial:; Pregnant women; Breastfeeding; Patients Enrolled in Other Clinical Studies; Patients who refuse to sign consent.